Study protocol for a randomized, triple-blind, placebo-controlled trial of modified Ukgan-san in patients with Hwabyung and neurotic symptoms - Top-Institutions - MDSpire

Protocol for a Randomized, Triple-Blind, Placebo-Controlled Trial Assessing Modified Ukgan-san in Individuals with Hwabyung and Associated Neurotic Symptoms

  • By

  • Hui-Yeong Park

  • Seok-In Yoon

  • Yerim Jeon

  • Jiho Pyun

  • Kieun Lee

  • Jae-Hong Yoo

  • Sun-Yong Chung

  • Jong Woo Kim

  • July 21, 2026

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Kyung-Hee University Oriental Medicine Hospital
    Kyung-Hee University Oriental Medicine Hospital

    Gangdong, Seoul

    Key Differentiators

    • Psychiatry
    • Traditional Medicine

  • #2

    Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine
    Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

    Nanjing, Jiangsu

    Key Differentiators

    • Chinese Medicine

  • #3

    Longhua Hospital of Shanghai University of Traditional Chinese Medicine
    Longhua Hospital of Shanghai University of Traditional Chinese Medicine

    Shanghai, Shanghai

    Key Differentiators

    • Chinese Medicine

  • #4

    Yinchuan Traditional Chinese Medicine Hospital
    Yinchuan Traditional Chinese Medicine Hospital

    Yinchuan, Ningxia

    Key Differentiators

    • Chinese Medicine

  • #5

    Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine
    Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

    Suzhou, Jiangsu

    Key Differentiators

    • Chinese Medicine

Original Source(s)

Study protocol for a randomized, triple-blind, placebo-controlled trial of modified Ukgan-san in patients with Hwabyung and neurotic symptoms

  • by Hui-Yeong Park, Seok-In Yoon, Yerim Jeon, Jiho Pyun, Kieun Lee, Jae-Hong Yoo, Sun-Yong Chung, Jong Woo Kim

  • July 21, 2026

Related Content

Latest developments in the use of e-cigarettes by people with schizophrenia spectrum disorders who smoke: a scoping review

Reframing Veteran Suicide Prevention—From Prevalence to Comparative Risk Trends

GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks